Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1982 2
1984 1
1988 1
1989 2
1990 1
1992 3
1993 1
1994 2
1995 1
1997 2
1999 1
2002 2
2003 1
2004 3
2005 2
2007 1
2008 1
2009 2
2010 3
2011 2
2012 2
2013 3
2014 6
2015 4
2016 3
2017 4
2018 5
2019 5
2020 3
2021 7
2022 2
2023 5
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Primary prostate urothelial carcinoma"
Page 1
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J Jr, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL Jr, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN. Boorjian SA, et al. Lancet Oncol. 2021 Jan;22(1):107-117. doi: 10.1016/S1470-2045(20)30540-4. Epub 2020 Nov 27. Lancet Oncol. 2021. PMID: 33253641 Free PMC article. Clinical Trial.
Patients were excluded if they had upper urinary tract disease, urothelial carcinoma within the prostatic urethra, lymphovascular invasion, micropapillary disease, or hydronephrosis. ...Repeat dosing at months 3, 6, and 9 was done in the absence of high-grade …
Patients were excluded if they had upper urinary tract disease, urothelial carcinoma within the prostatic urethra, lymp …
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial.
Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath EI, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV. Yu EY, et al. Lancet Oncol. 2021 Jun;22(6):872-882. doi: 10.1016/S1470-2045(21)00094-2. Epub 2021 May 12. Lancet Oncol. 2021. PMID: 33991512 Clinical Trial.
BACKGROUND: Locally advanced or metastatic urothelial carcinoma is generally incurable and has scarce treatment options, especially for cisplatin-ineligible patients previously treated with PD-1 or PD-L1 therapy. ...METHODS: EV-201 is a multicentre, single-arm, phas …
BACKGROUND: Locally advanced or metastatic urothelial carcinoma is generally incurable and has scarce treatment options, espec …
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
McGregor BA, Sonpavde GP, Kwak L, Regan MM, Gao X, Hvidsten H, Mantia CM, Wei XX, Berchuck JE, Berg SA, Ravi PK, Michaelson MD, Choueiri TK, Bellmunt J. McGregor BA, et al. Ann Oncol. 2024 Jan;35(1):91-97. doi: 10.1016/j.annonc.2023.09.3114. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871703 Clinical Trial.
BACKGROUND: The antibody-drug conjugates sacituzumab govitecan (SG) and enfortumab vedotin (EV) are standard monotherapies for metastatic urothelial carcinoma (mUC). Given the different targets and payloads, we evaluated the safety and efficacy of SG + EV in a phase …
BACKGROUND: The antibody-drug conjugates sacituzumab govitecan (SG) and enfortumab vedotin (EV) are standard monotherapies for metastatic …
Urothelial carcinoma in the prostatic urethra and prostate: current controversies.
Liedberg F, Chebil G, Månsson W. Liedberg F, et al. Expert Rev Anticancer Ther. 2007 Mar;7(3):383-90. doi: 10.1586/14737140.7.3.383. Expert Rev Anticancer Ther. 2007. PMID: 17338657 Review.
We reviewed the literature on urothelial carcinoma in the prostatic urethra and prostate. We concluded that the incidence of urothelial carcinoma in the prostatic urethra and prostate is probably underestimated. ...Resectosc …
We reviewed the literature on urothelial carcinoma in the prostatic urethra and prostate. We concluded that the …
Pulmonary manifestations of urothelial carcinoma of the bladder.
Agrawal A, Sahni S, Vulisha AK, Gumpeni R, Shah R, Talwar A. Agrawal A, et al. Respir Med. 2017 Jul;128:65-69. doi: 10.1016/j.rmed.2017.05.006. Epub 2017 May 16. Respir Med. 2017. PMID: 28610671 Free article. Review.
Urothelial carcinoma (Transitional cell carcinoma) of the bladder is the pre-dominant histological type of bladder cancer in the United States and Europe. ...The pulmonary manifestations of urothelial carcinoma of the bladder inclu …
Urothelial carcinoma (Transitional cell carcinoma) of the bladder is the pre-dominant histological type o …
Impact of smoking on urologic cancers: a snapshot of current evidence.
Kumar R, Matulewicz R, Mari A, Moschini M, Ghodoussipour S, Pradere B, Rink M, Autorino R, Desai MM, Gill I, Cacciamani GE. Kumar R, et al. World J Urol. 2023 Jun;41(6):1473-1479. doi: 10.1007/s00345-023-04406-y. Epub 2023 Apr 24. World J Urol. 2023. PMID: 37093319 Free PMC article. Review.
PURPOSE: The purpose of this paper is to present evidence regarding the associations between smoking and the following urologic cancers: prostate, bladder, renal, and upper tract urothelial cancer (UTUC). ...PubMed was queried for evidence-based analyses and trials …
PURPOSE: The purpose of this paper is to present evidence regarding the associations between smoking and the following urologic cancers: …
Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US.
Mathew Thomas V, Jo Y, Tripathi N, Roy S, Chigarira B, Narang A, Gebrael G, Hage Chehade C, Sayegh N, Galarza Fortuna G, Ji R, Campbell P, Li H, Agarwal N, Gupta S, Swami U. Mathew Thomas V, et al. JAMA Netw Open. 2024 May 1;7(5):e249417. doi: 10.1001/jamanetworkopen.2024.9417. JAMA Netw Open. 2024. PMID: 38696168 Free PMC article.
IMPORTANCE: The treatment paradigm for advanced urothelial carcinoma (aUC) has undergone substantial transformation due to the introduction of effective, novel therapeutic agents. ...Patients receiving treatment for 2 or more different types of cancer or participati …
IMPORTANCE: The treatment paradigm for advanced urothelial carcinoma (aUC) has undergone substantial transformation due to the …
Urologic cancer in Indonesia.
Umbas R, Safriadi F, Mochtar CA, Djatisoesanto W, Hamid AR. Umbas R, et al. Jpn J Clin Oncol. 2015 Aug;45(8):708-12. doi: 10.1093/jjco/hyv066. Epub 2015 Jun 16. Jpn J Clin Oncol. 2015. PMID: 26085688 Review.
More than half of patients with kidney cancer are diagnosed in the advanced stage. Besides renal cell carcinoma, there are significant number of people affected with squamous cell and transitional cell carcinoma because of kidney stones. …
More than half of patients with kidney cancer are diagnosed in the advanced stage. Besides renal cell carcinoma, there are sig …
Primary urothelial carcinoma of the prostate: A rare case report.
Zhou J, Yang C, Lu Z, Zhang L, Yin Y, Tai S, Liang C. Zhou J, et al. Medicine (Baltimore). 2019 Jan;98(3):e14155. doi: 10.1097/MD.0000000000014155. Medicine (Baltimore). 2019. PMID: 30653154 Free PMC article.
RATIONALE: Prostatic urothelial carcinoma is a rare disease. Medical misdiagnosis rates remain high because there are no specific clinical symptoms or imaging features, which decreases patient survival. ...The patient underwent transrectal ultrasound-g …
RATIONALE: Prostatic urothelial carcinoma is a rare disease. Medical misdiagnosis rates remain high because there are n …
ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.
Monteiro LL, Witjes JA, Agarwal PK, Anderson CB, Bivalacqua TJ, Bochner BH, Boormans JL, Chang SS, Domínguez-Escrig JL, McKiernan JM, Dinney C, Godoy G, Kulkarni GS, Mariappan P, O'Donnell MA, Rentsch CA, Shah JB, Solsona E, Svatek RS, van der Heijden AG, van Valenberg FJP, Kassouf W. Monteiro LL, et al. World J Urol. 2019 Jan;37(1):51-60. doi: 10.1007/s00345-018-2438-9. Epub 2018 Aug 14. World J Urol. 2019. PMID: 30109483 Review.
RESULTS: Recommendations were summarized with regard to staging; management of primary and recurrent LG Ta and high risk disease, positive urine cytology with negative white light cystoscopy and prostatic urethral involvement; indications for timely cystectomy; and …
RESULTS: Recommendations were summarized with regard to staging; management of primary and recurrent LG Ta and high risk disease, pos …
77 results